Loading...
The FDA's approval of flibanserin for hypoactive sexual desire disorder (HSDD) in premenopausal women was accompanied by media attention along with concerns that the medication's modest efficacy might be outweighed by its side effects. In a meta-analysis of eight randomized trials (5 published, 3 unpublished) involving 5914 pre- and postmenopausal women, flibanserin yielded the following outcomes compared with placebo:
Mean number of satisfying sexual events per month increased by 0.5 events (from a baseline of 2.5 events monthly).
Mean increase in a sexual desire intensity score was 1.6 points (on a 0–84 scale).
Mean increase in the desire domain of the Female Sexual Function Index was 0.3 points (on a 1.2–6.0 scale).
All of these differences …